Tristel (TSTL) Price & Analysis

Compare

17 Followers

TSTL Stock Chart & Stats

425.00 p

2.50 p(0.59%)

At close: Jan 09 4:00 PM EST

425.00 p

2.50 p(0.59%)

Day’s Range― - ―

52-Week Range260.00 p - 445.00 p

Previous CloseN/A

Volume2.07K

Average Volume (3M)75.90K

Market Cap

£188.13M

Enterprise Value186.90M

Total Cash (Recent Filing)£13.29M

Total Debt (Recent Filing)£5.82M

Price to Earnings (P/E)12.6

Beta0.74

Next Earnings

Oct 26, 2026

EPS Estimate

0.09

Next Dividend Ex-DateN/A

Dividend Yield3.48%

Share Statistics

EPS (TTM)0.09

Shares Outstanding47,931,540

10 Day Avg. Volume83,961

30 Day Avg. Volume75,902

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)5.93

Price to Sales (P/S)4.21

P/FCF Ratio20.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.17

Revenue Forecast (FY)£51.14M

Bulls Say, Bears Say

Bulls Say

High Profitability And Margin ProfileSustained high gross and EBITDA margins indicate a durable product-level advantage and pricing power in infection-control consumables. Strong margins support reinvestment in commercial and clinical programs, fund dividends and absorb near-term operating investment without structural margin erosion.

Strong Balance Sheet And Cash GenerationA debt-free position with material cash reserves and robust operating cash generation gives lasting financial flexibility. This strengthens capacity to fund international rollouts, clinical studies and M&A, while supporting a progressive dividend policy through economic cycles.

U.S. Commercial Traction And Clinical ValidationEarly U.S. scale, growing procedures and distributor/OEM partnerships plus guideline inclusions create a structural growth runway. Clinical validation and expanding channel coverage increase adoption potential and recurring revenues as the business builds commercial scale.

Bears Say

China / APAC WeaknessExposure to APAC, especially China, creates durable regional demand risk when local policy, hospital financing and private provider solvency change. Slower recovery or structural private market contraction could limit international growth against otherwise strong European and U.S. progress.

Declining Free Cash Flow GrowthA notable drop in free cash flow growth, if persistent, can constrain funding for commercial expansion, clinical trials and dividends. Even with positive operating cash, weaker FCF growth reduces financial optionality and raises sensitivity to higher capex or working capital needs.

Rising Operating Costs From Investment/in-sourcingElevated operating spend tied to hires, in-sourcing production and succession costs pressures near-term margins and cash conversion. These are strategic but raise execution risk: if commercial scaling or expected H2 savings lag, margin and ROCE targets could be harder to sustain.

Tristel News

Tristel to Outline Strategy at ShareSoc Growth Event in Leeds

An announcement from Tristel ( ($GB:TSTL) ) is now available. Tristel plc, the AIM-listed infection prevention company headquartered...

18h ago

Tristel plc Earnings Call Highlights Growth Momentum

Tristel plc (($GB:TSTL)) has held its Q2 earnings call. Read on for the main highlights of the call....

15d ago

Tristel Director’s Associate Increases Stake in Infection Prevention Specialist

Tristel ( ($GB:TSTL) ) has issued an update. Tristel plc, the AIM‑quoted infection prevention specialist, develops chlorine dioxide‑based...

15d ago

Tristel Delivers Double-Digit Growth as US Business Surges and Product Portfolio Expands

The latest announcement is out from Tristel ( ($GB:TSTL) ). Tristel reported a strong first half to 31...

17d ago

Tristel Issues New Shares Following Employee Option Exercise

Tristel ( ($GB:TSTL) ) has issued an update. Tristel plc, the AIM-listed infection prevention specialist focused on chlorine...

1M ago

Tristel Issues New Shares After Employee Option Exercise

Tristel ( ($GB:TSTL) ) has shared an announcement. Tristel plc has issued and allotted 71,500 new ordinary shares...

1M ago

Tristel Sets 2 March Date for Interim Results and Investor Briefings

Tristel ( ($GB:TSTL) ) has issued an update. Tristel plc has announced that it will publish its interim...

1M ago

Tristel Delivers Strong First Half as CEO Plans Exit for US Role

Tristel ( ($GB:TSTL) ) has issued an announcement. Tristel reported a strong first half to the financial year...

2M ago

Tristel Increases Share Capital After Employee Option Exercise

An announcement from Tristel ( ($GB:TSTL) ) is now available. Tristel plc has issued and allotted 84,500 new...

2M ago

Tristel Director Increases Shareholding, Signaling Confidence in Company Growth

Tristel ( ($GB:TSTL) ) just unveiled an announcement. Tristel plc announced that Tom Jenkins, a Non-Executive Director, purchased...

3M ago

TSTL FAQ

What was Tristel PLC’s price range in the past 12 months?

Tristel PLC lowest share price was 260.00 p and its highest was 445.00 p in the past 12 months.

What is Tristel PLC’s market cap?

Tristel PLC’s market cap is £188.13M.

When is Tristel PLC’s upcoming earnings report date?

Tristel PLC’s upcoming earnings report date is Oct 26, 2026 which is in 221 days.

How were Tristel PLC’s earnings last quarter?

Tristel PLC released its earnings results on Mar 02, 2026. The company reported 0.094 p earnings per share for the quarter, beating the consensus estimate of 0.092 p by 0.002 p.

Is Tristel PLC overvalued?

According to Wall Street analysts Tristel PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tristel PLC pay dividends?

Tristel PLC pays a Semiannually dividend of 8.52 p which represents an annual dividend yield of 3.48%. See more information on Tristel PLC dividends here

What is Tristel PLC’s EPS estimate?

Tristel PLC’s EPS estimate is 0.09.

How many shares outstanding does Tristel PLC have?

Tristel PLC has 47,931,540 shares outstanding.

What happened to Tristel PLC’s price movement after its last earnings report?

Tristel PLC reported an EPS of 0.094 p in its last earnings report, beating expectations of 0.092 p. Following the earnings report the stock price went down -0.75%.

Which hedge fund is a major shareholder of Tristel PLC?

Currently, no hedge funds are holding shares in GB:TSTL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tristel Stock Smart Score

Neutral

Fundamentals

Return on Equity

23.64%

Trailing 12-Months

Asset Growth

6.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tristel PLC

Tristel plc (TSTL) is a UK-based company that specializes in infection prevention and control, primarily serving the healthcare sector. The company focuses on developing and manufacturing infection control products, particularly in the areas of surface disinfection and medical device decontamination. Tristel's core offerings include its proprietary chlorine dioxide-based disinfectant products, which are designed to provide effective and safe disinfection solutions across various healthcare environments.